Infigratinib

(Truseltiq®)

Truseltiq®

Drug updated on 11/29/2023

Dosage FormCapsule (oral; 25 mg, 100 mg)
Drug ClassKinase inhibitors
Ongoing and
Completed Studies
ClinicalTrials.gov

Indication

  • For the treatment of adults with previously treated, unresectable locally advanced or metastatic cholangiocarcinoma with a fibroblast growth factor receptor 2 (FGFR2) fusion or other rearrangement as detected by an FDA-approved test.

Product Monograph / Prescribing Information

Document TitleYearSource
Truseltiq (infigratinib) Prescribing Information.2021QED Therapeutics Inc., Brisbane, CA

Randomized Controlled Trials


Sex Distribution:

F:57%
M:43%
61Subjects

Year:

2018

Source:Journal of Clinical Oncology